Krakow, Poland – 21 November 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that preclinical data from SEL120, a CDK8 inhibitor in development for the treatment of acute myeloid leukemia, has been accepted for…
Selvita demonstrates dynamic business growth in Q3 2018
Krakow, Poland – 20 November 2018 – Selvita (WSE: SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, has recently published quarterly financial results demonstrating its continued dynamic business growth. In Q3 2018 Selvita Group recognized total commercial revenue (not…
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Krakow, Poland – 8 November 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, will present a new data from SEL120 program at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. The conference is taking place…
Selvita presents at BIO-Europe 2018
Kraków, Poland – 2 November 2018 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, will participate and present at the BIO-Europe 2018 conference, which is taking place on November 5-7, 2018, in Copenhagen, Denmark. The…
Selvita to present new data from its oncology programs at the upcoming SITC 2018
Krakow, Poland – 31 October 2018 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer…
Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice
Krakow, Poland – 03 October – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, will participate and present during the “Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice”, which is taking place 3 –…